



- (51) **International Patent Classification:**
C07C 275/42 (2006.01) *C07C 273/02* (2006.01)
C07C 275/36 (2006.01) *C07B 57/00* (2006.01)
- (21) **International Application Number:**
PCT/KR2011/009579
- (22) **International Filing Date:**
13 December 2011 (13.12.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
10-2010-0129080
16 December 2010 (16.12.2010) KR
- (71) **Applicant (for all designated States except US):** AMIN-OLUX, INC. [KR/KR]; Jungbu Building 6th Flr, 968-6 Daechi-dong, Gangnam-gu, Seoul 135-848 (KR).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** CHANG, Rae Kyu [KR/KR]; Imaechon Chonggu, Apt. 613-102, Imae-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-905 (KR). AHN, Yun Soo [KR/KR]; Gyeongnam Apt. 1-106, Bangbae 3-dong, Seocho-gu, Seoul 137-851 (KR). JUNG, Hee-jung [KR/KR]; Jungwon acevil 205, 1714-2, Sangdaewon 1-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do 462-121 (KR). GA, Hyerim [KR/KR]; Daelim Apt. 107-204, Susaek-dong, Eunpyeong-gu, Seoul 122-755 (KR). MAENG, Juwan [KR/KR]; Baekhyeon Maeul 2911-801, Dongbaek-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-710 (KR). KOH, Young-Kook [KR/KR]; Geumhwa Maeul 406-1301, Sanggal-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-905 (KR). LEE, Young Hee [KR/KR]; Xi Apt. 108-1202, Jungnim-ri, Jochiwon-eup, Yeongi-gun, Chungcheongnam-do 339-884 (KR). LEE, Kwang Jae [KR/KR]; Wolgotdong Poonglim 1 Cha Apt., 112-402,

Wolgot-dong, Siheung-si, Gyeonggi-do 429-901 (KR). KIM, Joonseo [KR/KR]; Hanshin lifevil 109-302, Bundang-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-030 (KR). LEE, Hyunil [KR/KR]; PangyowonMaeul Apt. 1111-304, 513, Pangyo-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-410 (KR). YOON, Heungsik [KR/KR]; Chonggu Apt. 511-2001, Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-500 (KR).

(74) **Agent:** KOREANA PATENT FIRM; Dong-Kyung Bld., Yeoksamdong 824-19, Kangnamku, Seoul 135-080 (KR).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) **Title:** ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME

(57) **Abstract:** The present invention relates to compounds 1, 1a (S-enantiomer) and 1b (R-enantiomer) of the following formula 1, and a method for preparing the same. [formula 1] The novel compound of the formula 1 is used as an important intermediate for preparing compounds 6, 6a (S-enantiomer) and 6b (R-enantiomer) of the following formula 6, which are 2,2'-binaphthol-3-aldehyde derivatives. Also, the present invention provides a method for preparing the compound of formula 1 with a very safe method at low cost. [formula 6]



Description

Title of Invention: ENANTIOMERICALLY PURE BINAPHTHOL DERIVATIVES AND METHOD FOR PREPARING THE SAME

Technical Field


- [1] The present invention relates to novel compounds used as an important intermediate in the method for preparing the compound of a 2,2'-binaphthol-3-aldehyde derivative and a method for preparing the same.

Background Art

- [2] Compounds where the hydrogen of the 2' hydroxyl group in 2,2'-binaphthol-3-aldehyde is selectively substituted are used for various uses. Among such compounds, the compound of the following formula 6, which is very useful for separating chiral amino alcohols or amino acids into their respective optical isomers by recognizing their chirality through an imine bond or for converting L-amino acid into D-amino acid or D-amino acid into L-amino acid, has been developed by the inventors of the present invention and patented (Korean Patent No. 0661280).

- [3] [formula 6]

- [4]



- [5] However, according to the prior art where the hydrogen of the 2' hydroxyl group in 2,2'-binaphthol-3-aldehyde is substituted, a mixed product of a compound where the hydrogen of the 2 hydroxyl group is substituted and a compound where the hydrogen of the 2' hydroxyl group is substituted is obtained because of the low selectivity for the 2' hydroxyl group. In particular, compounds where the hydrogen of the 2 hydroxyl group is substituted are obtained in more amounts. Such mixed product has a problem that the efficiency for preparing the target product is greatly deteriorated because the mixture cannot be easily separated, and thus there is a difficulty such as that the alkylation process must be carried out after protecting the 2 hydroxyl group with a protecting group to achieve substitution of the hydrogen of the 2' hydroxyl group. Thus, a technology for increasing the selectivity for hydrogen of the 2' hydroxyl group, which prevents byproducts from being generated, is required.

- [6] Meanwhile, the novel compounds of the present invention, binaphthol derivatives, are represented by the following formula 1, and for the preparation of said compound,


scale.

Mode for the Invention

[26] The present invention relates to a compound of the following formula 1 and a method for preparing the same.

[27] [formula 1]

[28]



[29] wherein X, Y, n, m, R₁ and R₂ are each as defined above.


[30] The compound of formula 1 can be used as an important intermediate for preparing the compound of formula 6, which is a 2,2'-binaphthol-3-aldehyde derivative.

[31] Also, the present invention provides a method for preparing compound 1 represented by formula 1, characterized by comprising the step of reacting the compound 2 represented by formula 2 with the compound 3 represented by formula 3 in the presence of a base.

[32] The reaction formula of the above preparation method is represented as follows:

[33] [Reaction formula 1]

[34]




[35] Solvents that can be used in the reaction can be exemplified by N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N-methyl pyrrolidone (NMP), tetrahydrofuran (THF), dichloromethane, etc., and DMF is preferable. Bases that can be used in the reaction can be exemplified by organic or inorganic bases such as Et₃N, NaH, NaOH, KOH, K₂CO₃, tetramethylethylenediamine (TMEDA), C₁~C₄ sodium or potassium alkoxide, etc., and NaOH is preferable. The amount of base used is 1~5 equivalents, and 2 equivalents are preferable. Also, the reaction takes place at a temperature of -40~30°C, and room temperature is preferable.

[36] Compound 2 of formula 2 can be prepared by applying and improving a known method [M. Noji, M. Nakajima and K. Koga. Tetrahedron Lett. 35 (1994), p. 7983-7984.] using compound 4 of formula 4 and compound 5 of formula 5, which are

very cheap. The following reaction is characterized by dissolving compound 4 into THF and adding compound 5 thereto, and adding CuCl(OH)-TMEDA to the mixed solution and carrying out the reaction in the presence of oxygen (details will be explained in example 1). Unlike the expensive binaphthol derivatives which have been used in prior art, the following compounds 4 and 5 are cheap and can be purchased in a large amount. Thus, the compound of formula 1, which is the target compound of the present invention, can be prepared economically.


[37] [formula 4]

[38]



[39] [formula 5]

[40]




[41] wherein X, Y, n and m are each as defined above.

[42] The reaction formula of the method for preparing compound 2 of formula 2 is represented as follows:

[43] [Reaction formula 2]

[44]



[45] Reaction a above is a reaction using CuCl(OH)-TMEDA mentioned above, and reaction b is a hydrolysis reaction of ester using a base. As the base and solvent in the

reactions, any base or solvent well known in the pertinent art can be used without limit.


[46] Reaction a and reaction b have advantages that they are both economic because they proceed almost quantitatively and they are safe because they do not have to use hazardous compounds. Thus, compound 2 of formula 2 can be prepared safely and economically by the above method.

[47] In case where compound 2 of formula 2 is synthesized by the above reactions, a racemic mixture is obtained. Thus, it is necessary to obtain an enantiomerically pure compound 2 of formula 2 therefrom. In the present invention, there is no limitation in the method for preparing an enantiomerically pure compound 2 of formula 2. As an example, compound 2 of formula 2 can be prepared in an enantiomerically pure form by resolution using cinchonidine, by applying and improving the method disclosed by Hovorka, M. et al. (Hovorka, M.; Stibor, I.; Holakovský, R.; Smisková, I.; Struzka, V. Czech Rep. (2001), CZ 287879 B6).

[48] The above exemplary method can be illustrated as the following reaction formula 3.

[49] [Reaction formula 3]


[50]



[51] The racemic mixture can be separated into enantiomerically pure compounds 2a (S-enantiomer) and 2b (R-enantiomer) by the reaction formula above, and if a reaction is carried out according to the following reaction formula 4 using compound 2a, the target compound 1a ($R_1=O$) or 1a ($R_1=H,H$) can be prepared.

[52] [Reaction formula 4]

[53]



[54] As a solvent for reaction c, as described for reaction formula 1 above, N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane, etc. can be used, and DMF is preferable. As a base used in reaction c, organic or inorganic bases such as Et₃N, NaH, NaOH, and C₁~C₄ sodium or potassium alkoxide, etc. can be used, and NaOH is

preferable. The amount of base used is 1~5 equivalents, and 2 equivalents are preferable. Also, reaction c takes place at a temperature of -40~30°C, and room temperature is preferable.


[55] As a solvent for reaction d, tetrahydrofuran, dioxane, dichloromethane, toluene, etc. can be used, and tetrahydrofuran is preferable. As a reducing agent used in reaction d, reducing agents well known in the field can be used without limit, and a mixture of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ and sodium borohydride is preferable.

[56] Also, the target compound 1b ($R_1=\text{O}$) or 1b ($R_1=\text{H,H}$) can be prepared by the method of reaction formula 4 using the compound 2b (R-enantiomer) obtained by reaction formula 3 as starting material.

[57] Compound 1, 1a or 1b of formula 1 of the present invention is used as an important intermediate for preparing the compound of the following formula 6, which is very useful for separating chiral amino alcohols or amino acids into their respective optical isomers by recognizing their chirality through an imine bond or for converting L-amino acid into D-amino acid or D-amino acid into L-amino acid.

[58] [formula 6]

[59]



[60] Hereinafter, the present invention is explained in more detail with reference to examples. However, the following examples are for exemplifying the present invention. Thus, the present invention is not limited to the following examples, but various modifications can be made thereto.

[61]

[62] Examples

[63] Example 1: Preparation of

[(S)-4-(2-(3-(3-p-tolylureido)benzyloxy)naphthalene-1-yl)-3-hydroxy-2-naphthoic acid] (Compound 1a ($R_1=\text{O}$))

[64] After dissolving (S)-3-hydroxy-4-(2-hydroxynaphthalene-1-yl)-2-naphthoic acid (9.0 g, 27 mmol) obtained by separating compounds 2 of reaction formula 2 prepared by applying and improving the known method of M. Noji, M. Nakajima and K. Koga. Tetrahedron Lett. 35 (1994), p. 7983-7984. by resolution using cinchonidine by applying and improving the technology disclosed by Hovorka, M. et al (Hovorka, M.; Stibor, I; Holakovský, R.; Smisková, I.; Struzka, V. Czech Rep. (2001), CZ 287879 B6) in 54 mL of DMF, 2.2 g of NaOH is added, and the mixture is stirred for 1 hour at

room temperature. After adding 1-(3-(bromomethyl)phenyl)-3-p-tolylurea (8.7 g, 27 mmol) to the reaction solution, the mixture is stirred for three hours, and the solid generated by adding water is filtered to obtain 15.3 g of the subject compound (yield: 99 %, purity: 96.5 %).

[65] ¹H NMR(DMSO-d₆, 400MHz), 8.60 (s, 1H, OH), 7.84(d, 1H, ArH), 7.79 (d, 1H, ArH), 7.73 (d, 1H, ArH), 7.43 (s(br), 1H, OH), 7.33~7.24 (m, 2H, ArH), 7.22~7.17 (m, 4H, ArH), 7.13 (s(br), 1H, NH), 7.08~7.00 (m, 4H, ArH), 6.92~6.88 (m, 3H, ArH), 6.84 (s(br), 1H, NH), 6.61 (d, 1H, ArH), 4.89 (dd, 2H, CH₂), 2.16 (s, 3H, CH₃).

[66] HPLC analysis condition: analysis instrument: HPLC (Agilent 1200 series); column: CAPCELL PAK UG120 C₁₈ (3.0 x 150 mm, Shisheido), temperature: 30 °C; solvent: 60% acetonitrile/H₂O (0.1% H₃PO₄) (6/4, v/v), flow rate: 0.5 mL/min, detection wavelength: 230nm

[67]

[68] Example 2: Preparation of

[(S)-1-(3-((1-(2-hydroxy-3-(hydroxymethyl)naphthalene-1-yl) naphthalene-2-yloxy)methyl)phenyl)-3-p-tolylurea] (Compound 1a (R₁=H,H))

[69] After dissolving the

(S)-4-(2-(3-(3-p-tolylureido)benzyloxy)naphthalene-1-yl)-3-hydroxy-2-naphthoic acid (15.3 g, 27.0 mmol) obtained in example 1 in THF (150 mL), BF₃·Et₂O (3.1 g) and sodium borohydride (15 g) are added sequentially. After stirring the reaction mixture at 60 °C for 8 hours, dilute hydrochloric acid is added to complete the reaction, and ethyl acetate (150 mL) and water (150 mL) are added. The subject compound is obtained by drying the organic layer with anhydrous MgSO₄ and filtering and condensing it (14.9 g, yield: 100 %, purity: 95.5 %).

[70] ¹H NMR (CDCl₃, 400 MHz), 7.91(d, 1H, ArH), 7.81 (d, 1H, ArH), 7.71 (d, 1H, ArH), 7.68 (s, 1H, ArH), 7.63 (s, 1H, ArH), 7.48 (s, 1H, OH), 7.37 (d, 1H, ArH), 7.34~7.29 (m, 2H, ArH), 7.25~7.12 (m, 5H, ArH), 7.03~6.87 (m, 4H, ArH), 6.61~6.57 (m, 2H, ArH), 6.00 (s, 1H, NH), 5.08 (d, 1H, 1/2CH₂OH), 4.91 (d, 1H, 1/2CH₂OH), 4.73 (dd, 2H, CH₂), 2.25 (s, 3H, CH₃).

[71] HPLC analysis condition: analysis instrument: HPLC (Agilent 1200 series); column: CAPCELL PAK UG120 C₁₈ (3.0 x 150 mm, Shisheido), temperature: 30 °C; solvent: 60% acetonitrile/H₂O (0.1 % H₃PO₄) (6/4, v/v), flow rate: 0.5 mL/min, detection wavelength: 230 nm

[72]

[73] Example 3: Preparation of

[(R)-4-(2-(3-(3-p-tolylureido)benzyloxy)naphthalene-1-yl)-3-hydroxy-2-naphthoic acid] (Compound 1b (R₁=O))

[74] The subject compound is obtained by the same method as example 1 using

(R)-3-hydroxy-4-(2-hydroxynaphthalene-1-yl)-2-naphthoic acid.

[75] ¹H NMR (DMSO-d₆, 400 MHz), 8.61 (s, 1H, OH), 7.87(d, 1H, ArH), 7.81 (d, 1H, ArH), 7.73 (d, 1H, ArH), 7.37~7.17 (m, 8H, ArH + NH), 7.07~6.89 (m, 9H, ArH + NH), 6.69 (d, 1H, ArH), 4.94 (dd, 2H, CH₂), 2.19 (s, 3H, CH₃)

[76]

[77] Example 4: Preparation of

[(R)-1-(3-((1-(2-hydroxy-3-(hydroxymethyl)naphthalene-1-yl)naphthalene-2-yloxy)methyl)phenyl)-3-p-tolylurea] (Compound 1b (R₁=H,H))


[78] The subject compound is obtained by the same method as example 1 using (R)-4-(2-(3-(3-p-tolylureido)benzyloxy)naphthalene-1-yl)-3-hydroxy-2-naphthoic acid.

[79] ¹H NMR (CDCl₃, 400MHz), 7.96 (d, 1H, ArH), 7.85 (d, 1H, ArH), 7.76 (d, 1H, ArH), 7.74 (s, 1H, ArH), 7.59 (s, 1H, ArH), 7.51 (d, 1H, ArH), 7.49 (d, 1H, ArH), 7.44~7.15 (m, 8H, ArH), 7.05~6.96 (m, 4H, ArH), 6.65 (d, 1H, ArH), 6.58 (s, 1H, NH), 5.19 (d, 1H, 1/2CH₂OH), 5.01 (d, 1H, 1/2CH₂OH), 4.78 (dd, 2H, CH₂), 2.26 (s, 3H, CH₃).

Claims

[Claim 1]

An enantiomerically pure compound represented by the formula 1:
[formula 1]



wherein,

X and Y are each independently selected from the group consisting of hydrogen; halogen; amino; nitro; cyano; C₁-C₁₀ alkyl non-substituted or substituted with at least one substituent selected from the group consisting of halogen, hydroxyl, amino, cyano, nitro and C₆-C₁₀ aryl; C₁-C₁₀ alkyl carbonyl; C₅-C₁₀ aryl; and C₁-C₁₀ alkoxy;

n and m are each independently an integer from 0 to 5;

R₁ is hydrogen or oxygen; and

R₂ is -NO₂, -NH(NHBOCNBOC), -NHCX'R₃, -NHS(=O)_aR₃ or -NHPO(OH)R₃, wherein

X' is oxygen or sulfur;

a is 1 or 2; and

R₃ is hydrogen; C₁-C₁₀ alkyl non-substituted or substituted with a halogen; -NR₄R₅; or OR₆,


wherein

R₄ to R₆ are each independently selected from the group consisting of hydrogen; C₁-C₁₀ alkyl non-substituted or substituted with a halogen; C₅-C₁₂ aryl non-substituted or substituted with at least one substituent selected from the group consisting of halogen, nitro, C₁-C₅ alkyl, C₁-C₅ alkoxy and C₁-C₅ perfluoroalkyl.

[Claim 2]

The compound according to Claim 1, wherein the compound is S-enantiomer represented by the formula 1a:

[formula 1a]




wherein X, Y, n, m, R₁ and R₂ are each as defined in Claim 1.

[Claim 3]

The compound according to Claim 1, wherein the compound is R-enantiomer represented by the formula 1b:

[formula 1b]




wherein X, Y, n, m, R₁ and R₂ are each as defined in Claim 1.

[Claim 4]


The compound according to Claim 2, wherein X and Y are each hydrogen; R₂ is 3-p-tolylureido; and R₁ is oxygen or hydrogen, and wherein the compound is represented by the formula 1a-1 or 1a-2:

[formula 1a-1]



or


[formula 1a-2]



[Claim 5]


The compound according to Claim 3, wherein X and Y are each hydrogen; R₂ is 3-p-tolylureido; and R₁ is oxygen or hydrogen, and wherein the compound is represented by the formula 1b-1 or 1b-2:

[formula 1b-1]



or


[formula 1b-2]




[Claim 6]

A method for preparing the compound represented by the formula 1, characterized by comprising the step of reacting the compound represented by the formula 2 with the compound represented by the formula 3 in an organic solvent in the presence of a base;


[formula 1]



[formula 2]



[formula 3]



3

wherein

X and Y are each independently selected from the group consisting of hydrogen; halogen; amino; nitro; cyano; C₁-C₁₀ alkyl non-substituted or substituted with at least one substituent selected from the group consisting of halogen, hydroxyl, amino, cyano, nitro and C₆-C₁₀ aryl; C₁-C₁₀ alkyl carbonyl; C₅-C₁₀ aryl; and C₁-C₁₀ alkoxy;

n and m are each independently an integer from 0 to 5;

R₁ is oxygen;

R₂ is -NO₂, -NH(NHBOCNBOC), -NHCX'R₃, -NHS(=O)_aR₃ or -

NHPO(OH)R₃, wherein

X' is oxygen or sulfur;

a is 1 or 2; and

R₃ is hydrogen; C₁-C₁₀ alkyl non-substituted or substituted with a halogen; -NR₄R₅; or OR₆,

wherein


R₄ to R₆ are each independently selected from the group consisting of hydrogen; C₁-C₁₀ alkyl non-substituted or substituted with a halogen; C₅-C₁₂ aryl non-substituted or substituted with at least one substituent selected from the group consisting of halogen, nitro, C₁-C₅ alkyl, C₁-C₅ alkoxy and C₁-C₅ perfluoroalkyl; and

Z is halogen.


[Claim 7] The method for preparing according to Claim 6, wherein the base is an organic base which is triethylamine (TEA) or tetraethylethylenediamine (TMEDA), or an inorganic base selected from the group consisting of NaH, NaOH, KOH and K₂CO₃.

[Claim 8] The method for preparing according to Claim 6 or 7, wherein the organic solvent is selected from the group consisting of N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone and tetrahydrofuran.

[Claim 9] The method for preparing according to Claim 6 or 7, wherein the compound represented by the formula 2 is the S-enantiomer which is represented by the formula 2a, and the compound represented by the formula 1 is the S-enantiomer which is represented by the formula 1a:




[formula 2a]




wherein X, Y, n, m, R₁ and R₂ are each as defined in Claim 6.

[Claim 10] The method for preparing according to Claim 6 or 7, wherein the

compound represented by the formula 2 is the R-enantiomer which is represented by the formula 2b, and the compound represented by the formula 1 is the R-enantiomer which is represented by the formula 1b:
[formula 1b]



[formula 2b]




wherein X, Y, n, m, R₁ and R₂ are each as defined in Claim 6.

[Claim 11]

The method for preparing the enantiomerically pure compound represented by formula 6 by using the compound according to any one of Claims 1 to 5, or the compound prepared by the method according to Claim 6 or 7:

[formula 6]



wherein X, Y, n, m and R₂ are each as defined in Claim 1.